Close
Eli Lilly is positioned at the intersection of the booming weight loss market and advancements in artificial intelligence. Despite a significant share price increase of 61% over the past year, the company remains a strong investment opportunity. Lilly's growth is driven by its diabetes and obesity medications, Mounjaro and Zepbound, which are expected to expand further with FDA approvals.
The company also has a $62 billion potential in Alzheimer's and eczema treatments, bolstered by recent FDA approvals. Additionally, Lilly's partnership with OpenAI highlights its commitment to leveraging AI in healthcare, particularly in addressing antimicrobial resistance. This multifaceted approach positions Lilly for sustained growth and market-beating returns in the coming years.
• AI in healthcare projected to become a $600 billion opportunity.
• Lilly partners with OpenAI to tackle antimicrobial resistance.
AI is expected to revolutionize healthcare, providing solutions for complex illnesses.
Generative AI could help pharmaceutical companies address underserved medical conditions.
OpenAI develops advanced AI technologies, collaborating with Lilly to enhance healthcare solutions.
The Motley Fool on MSN.com 14month
Isomorphic Labs, the AI drug discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600
How to level up your teaching with AI. Discover how to use clones and GPTs in your classroom—personalized AI teaching is the future.
Trump's Third Term? AI already knows how this can be done. A study shows how OpenAI, Grok, DeepSeek & Google outline ways to dismantle U.S. democracy.
Sam Altman today revealed that OpenAI will release an open weight artificial intelligence model in the coming months. "We are excited to release a powerful new open-weight language model with reasoning in the coming months," Altman wrote on X.
Log in
Sign Up
AI Tools - Popular
AI Tools - Categories
GPTs - Categories
AI for Jobs
Key AI Highlights in this Article
Key AI Terms Mentioned in this Article
Companies Mentioned in this Article
